Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Orencia Pharmacovigilance Plan Sufficient For Approval, Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Arthritis Drugs Advisory Committee unanimously recommends approval of the rheumatoid arthritis therapy abatacept.
Advertisement

Related Content

Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
Orencia Launch Anticipated By Bristol In Early 2006
Bristol Consolidates Worldwide Pharmaceutical Operations
Will Manufacturing Issues Hobble Abatacept?
Will Manufacturing Issues Hobble Abatacept?
Bristol Abatacept Infection, Malignancy Risk To Be Considered By Advisory Committee
Bristol Abatacept Infection, Malignancy Risk To Be Considered By Advisory Committee
Bristol's Abatacept Shows Elevated Infection Risk In Phase III Safety Study
Abatacept Launch Will Be Bolstered By Unmet Need In RA Market – Bristol

Topics

Advertisement
UsernamePublicRestriction

Register

PS062983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel